New Delhi, Nov. 15 -- Sun Pharmaceutical Industries Ltd's second quarter figures have outrun estimates, showing that the firm is getting back on the recovery path.
Overall, Q2 revenues were about 16.1% higher than a year ago, driven by steady growth in its home market and integration of the Pola Pharma Inc. business in Japan in the rest of the world business. Sun Pharma's profit before tax increased by about 8% year-on-year (y-o-y).
The US market, however, has been seeing signs of sluggishness. Revenues from this region were flat compared with last year. Analysts have noted that headline growth has been largely in line with estimates, though US sales, excluding sales of its subsidiary Taro Pharmaceuticals, were much weaker than anticipate...